Male Vitality Supplement Guide: What The Evidence Shows

Walk the male vitality shelf and the same nine or ten names recur: maca, tribulus, horny goat weed, muira puama, catuaba, ashwagandha, L-arginine, green tea, and caffeine somewhere near the bottom. The packaging varies enormously. The ingredient list barely does.

That convergence is not evidence of a consensus. It is a supply chain. These are the botanicals a contract manufacturer can source in bulk, blend, and put a label on without a new safety file, and the reason they recur is commercial rather than clinical. It is still worth knowing which of them have been tested and what happened, because the answers are genuinely different from one row to the next.

One thing is worth fixing in your head before the ingredient sections: the amount matters more than the name. An ingredient with an excellent trial behind it is doing nothing at a hundredth of that trial's dose.

If one ingredient in this aisle has earned its place, it is L-arginine, and the reason is mechanistic rather than traditional. Arginine is the substrate the body converts into nitric oxide, and nitric oxide is the signal that relaxes the smooth muscle lining blood vessels. That is the same pathway the prescription drugs in this area work on, from a different point along it.

The original crossover trial gave 5,000 mg a day for six weeks and found the improvement was concentrated in men whose baseline nitric oxide output was already low. That is a useful finding and an inconvenient one for marketing: it suggests the ingredient corrects a deficit rather than adding a capability.

The 2019 meta-analysis is the reference most worth reading. It pooled the available trials and found a benefit over placebo, and it attached a range to that benefit: between 1,500 and 5,000 mg a day. Below that range the pooled data has nothing to say.

Two practical notes. Oral arginine's pharmacokinetics are unhelpful, with substantial first-pass metabolism meaning a swallowed gram is not a gram delivered. And oral arginine lowers blood pressure in pooled analysis, with a dose relationship behind it, which is worth raising with whoever prescribes your antihypertensives before you add a gram or three a day on top.

Tribulus terrestris is sold on a testosterone story, so it is worth separating the story from the result, because they point in different directions.

The result first. Kamenov and colleagues ran a randomised, double-blind, placebo-controlled trial at 1,500 mg a day, taken as six 250 mg tablets, and reported improvement in both erectile function and sexual desire scores. That is a real trial with a real result and the dose is specific: six tablets a day, not one.

Now the story. Neychev and Mitev tested the hormonal premise directly in young men and found tribulus did not influence androgen production. So whatever the Kamenov result is, the testosterone explanation printed on the front of the boxes is not it.

A later placebo-controlled trial at a lower daily amount did not reproduce the benefit, and a 2025 review of tribulus supplementation reads the literature as mixed rather than settled. The 2026 meta-analysis is the most recent word and it is cautious about the size of any effect.

One safety note that rarely makes the marketing. A published case report describes severe nephrotoxicity in a patient taking tribulus. A single case report is not a population risk, but it is the reason anybody with kidney disease should treat this particular ingredient as a conversation rather than a purchase.

Maca is a Peruvian root vegetable eaten as food at high altitude, which gives it a different safety profile from most of this shelf. Its research record is modest, repeatable, and honest about its own limits.

The Gonzales trial gave 1,500 mg or 3,000 mg a day for twelve weeks and reported improved sexual desire at both amounts. The detail that makes it worth citing is negative: serum testosterone and oestradiol were measured and did not change. A supplement that improves a subjective outcome without moving the hormone it is marketed on is telling you the marketing is wrong, not that the result is.

A later trial at 2,400 mg a day for twelve weeks found subjective improvement on questionnaire scores in men with mild dysfunction. The systematic review that pooled this work described the evidence as limited and the trials as small, which is the fair summary.

The number to carry away is the dose. Every maca result in the literature sits between 1,500 and 3,000 mg a day, sustained for around three months. That is one and a half to three grams, daily, of a single ingredient.

Ashwagandha is the ingredient in this aisle with the most convincing controlled data, and the gap between its trial dose and its typical label dose is correspondingly the most striking.

Ambiye and colleagues gave 675 mg a day of root extract, split across three doses, for ninety days, and reported improvement in semen parameters and serum testosterone in oligospermic men. That is the strongest result any single ingredient on this shelf has produced, and 675 mg a day for three months is what it cost.

The stress trial ran 240 mg a day for sixty days and reported reductions in cortisol and in anxiety scores. A later crossover study looked specifically at hormonal outcomes in men, and a meta-analysis has since pooled the sexual-function work. One smaller trial tested it in erectile dysfunction specifically and was less encouraging.

Against that, two case series. One from the United States and one from India both describe liver injury associated with ashwagandha supplements. The LiverTox monograph gathers the picture, and the NCCIH summary is the plain-language version. The signal is uncommon and it is real, and it is a reason to stop and get advice if jaundice, dark urine or unexplained fatigue appear.

Horny goat weed is the most scientifically interesting ingredient in the aisle and the one most often oversold, and both facts come from the same finding.

Dell'Agli and colleagues showed that icariin, the flavonoid behind the plant's reputation, is a potent inhibitor of human phosphodiesterase-5. That is the same enzyme the prescription drugs in this area inhibit. The mechanism is genuinely shared, which is why the comparison keeps getting made.

The comparison then falls apart on potency and on delivery. Icariin's half-maximal inhibitory concentration in that work was 5.9 micromolar, some four orders of magnitude weaker than sildenafil's. Follow-up work explored the same activity in vitro. The compounds that came close to matching a prescription drug were synthetic derivatives of icariin made in a laboratory, not icariin itself, and not anything sold in a jar.

The pharmacokinetic study is the part that settles it. Prenylflavonoids taken by mouth reach low plasma concentrations, so the concentration that inhibited the enzyme in glassware is not the concentration a swallowed capsule produces in tissue. The one placebo-controlled human trial of the compound ran in a different condition entirely.

A systematic review of the genus covers traditional uses, chemistry and toxicology together and is the best single starting point if you want the whole picture rather than the headline.

These two are on almost every label in the category and they have the thinnest records in it, which is worth stating plainly rather than leaving to be inferred from an absent citation.

Muira puama's human literature amounts to one open-label study in 202 women of a combination product containing ginkgo as well. The rest is preclinical: work in rat tissue on a blend of ginger, citrulline and muira puama, a follow-up in aging rats, central nervous system effects in rodents, and a chemical characterisation of the plant.

Catuaba has a problem before the evidence question is reached. Kletter and colleagues analysed fourteen commercial catuaba samples and found most were not the plant their own labels named, because several species travel under the one trade name. What exists beyond that is relaxation of isolated rabbit tissue, antioxidant and antifatigue effects in mice and neuroprotection work. None of it is a person.

Green tea extract is rarely the reason anyone buys a male vitality product, and it is frequently the ingredient with the most published safety literature attached.

The United States Pharmacopeia review examined green tea extract and liver signals in detail and is the most thorough treatment available. Navarro and colleagues looked at catechins in dietary supplements and hepatotoxicity specifically. The NCCIH page is the readable summary. The case reports involve concentrated extracts at daily catechin intakes far above what a cup of tea supplies, which is the distinction that matters when you read the row on a label.

Caffeine is simpler and better characterised than anything else in this aisle. The standard review of caffeine and human health puts up to 400 mg a day for healthy adults in the range not associated with adverse effects. A 5 oz cup of ground roasted coffee is about 85 mg. Those two figures let you place any caffeine row on any label in about five seconds, which is more than can be said for the botanicals above it.

Added sugar on a chewable deserves the same arithmetic. The 2021 American Heart Association guidance and the cohort work on added sugar and cardiovascular mortality are the context for a row taken daily for months.

Everything above concerns whether an ingredient works. The sharpest published risk in this aisle is a different question entirely: whether the ingredient in the jar is the ingredient on the label.

Campbell and colleagues documented adulteration of purported herbal and natural sexual performance products with prescription drugs. Screening work has found synthetic PDE-5 inhibitors and their analogues in products sold as herbal. An analysis of regulator warnings catalogued unapproved pharmaceutical ingredients in dietary supplements across years of notices.

This matters more than any efficacy question on this page. A man avoiding a prescription because of a nitrate he takes for his heart, who buys a herbal product instead, and whose herbal product contains an undeclared PDE-5 inhibitor, has walked into exactly the interaction he was avoiding, without knowing he did. The defence is unglamorous: buy from a seller with an address, a telephone number and a refund route, prefer a manufacturer that will name a testing laboratory, and treat any product promising a drug-like effect on a drug-like timescale as the most likely to be adulterated, since that promise is hard to keep with plants.

Read ten male vitality labels and they will all say some version of “supports healthy circulation” or “supports male vitality”. That uniformity is legal architecture rather than coincidence.

A dietary supplement in the United States may make structure and function claims. It may say an ingredient supports a normal body function. It may not say the product diagnoses, treats, cures or prevents a disease, because a product that does that is a drug and is regulated as one. Erectile dysfunction is a diagnosable condition, so nothing sold on this shelf may claim to treat it.

The practical consequence is that the front of the box carries almost no information. Every product says the same thing because every product is required to. The information is on the back, in milligrams.

The NCCIH overview of dietary and herbal supplements and its Herbs at a Glance index are the two most useful non-commercial starting points for anyone who wants to check a claim independently.

No guide to this aisle is honest without the sentence the aisle exists to avoid: persistent difficulty with erections is a recognised clinical sign, and it has a work-up.

Pooled analysis associates erectile dysfunction with cardiovascular disease, which is why it is taken seriously as a marker rather than treated purely as a quality-of-life complaint. The vascular bed involved is narrower than the coronary bed, so it can register a problem earlier.

The American Urological Association guideline and the European Association of Urology guidelines both set out what an assessment involves, and neither recommends a botanical supplement as a first step. The MedlinePlus page is the plain-language version of the same material.

The lifestyle evidence is the part most worth acting on regardless of what else you decide: weight, activity and cardiovascular risk factor modification produced measurable improvement in pooled analysis. That is a larger documented effect than anything else on this page, and none of it makes a supplement a bad purchase. It makes one a second decision rather than a first.

Read the third column as the cost of the second. An ingredient with an excellent trial behind it is not delivering that trial's result at a fraction of that trial's dose.